Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
The Lancet Infectious Diseases,  Clinical Article

Cornely OA et al. – Fidaxomicin could be an alternative treatment for infection with C difficile, with similar efficacy and safety to vancomycin.

Methods
  • In this multicentre, double-blind, randomised, non-inferiority trial, the authors enrolled patients from 45 sites in Europe and 41 sites in the USA and Canada between April 19, 2007, and Dec 11, 2009.
  • Eligible patients were aged 16 years or older with acute, toxin-positive C difficile infection.
  • Patients were randomly allocated (1:1) to receive oral fidaxomicin (200 mg every 12 h) or oral vancomycin (125 mg every 6 h) for 10 days.
  • The primary endpoint was clinical cure, defined as resolution of diarrhoea and no further need for treatment.
  • An interactive voice-response system and computer-generated randomisation schedule gave a randomisation number and medication kit number for each patient.
  • Participants and investigators were masked to treatment allocation.
  • Non-inferiority was prespecified with a margin of 10%.
  • Modified intention-to-treat and per-protocol populations were analysed.

Results
  • Of 535 patients enrolled, 270 were assigned fidaxomicin and 265 vancomycin.
  • After 26 patients were excluded, 509 were included in the modified intention-to-treat (mITT) population.
  • 198 (91•7%) of 216 patients in the per-protocol population given fidaxomicin achieved clinical cure, compared with 213 (90•6%) of 235 given vancomycin, meeting the criterion for non-inferiority (one-sided 97.5% CI -4.3%).
  • Non-inferiority was also shown for clinical cure in the mITT population, with 221 (87.7%) of 252 patients given fidaxomicin and 223 (86.8%) of 257 given vancomycin cured (one-sided 97.5% CI -4.9%).
  • nalyses of the primary endpoint in the mITT population, outcomes in the two treatment groups did not differ significantly; although patients receiving concomitant antibiotics for other infections had a higher cure rate with fidaxomicin (46 [90.2%] of 51) than with vancomycin (33 [73.3%] of 45; p=0.031).
  • Occurrence of treatment-emergent adverse events did not differ between groups. 20 (7.6%) of 264 patients given at least one dose of fidaxomicin and 17 (6.5%) of 260 given vancomycin died.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Infectious Disease

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Infectious Disease Articles

1 Hand dryers can spread bacteria in public toilets, research finds University of Leeds Health News, December 1, 2014

2 Bacterial product could cure viral infections, scientists say Pennsylvania State University Health and Medicine News, November 21, 2014

3 Deconstructing Ebola to find its weakness and defeat it American Chemical Society News, December 5, 2014

4 Gene found to be a factor in the body's immune response to flu vaccine University of Alberta Faculty of Medicine & Dentistry News, December 16, 2014

5 Antibiotics get a time-out McGill University Health Centre News, November 20, 2014

6 Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: Systematic review and meta-analysis Full Text BMC Infectious Diseases, December 17, 2014    Free full text    Evidence Based Medicine    Review Article

7 Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: A systematic review and meta-analysis International Journal of Antimicrobial Agents, October 7, 2014    Evidence Based Medicine    Review Article

8 Antistaphylococcal penicillins versus cephalosporins for definitive treatment of methicillin-susceptible bacteraemia: A systematic review and meta-analysis International Journal of Antimicrobial Agents, September 30, 2014    Evidence Based Medicine    Review Article

9 Risk factors for periprosthetic joint infection after total joint arthroplasty: A systematic review and meta-analysis Journal of Hospital Infection, December 5, 2014    Evidence Based Medicine    Review Article

10 Inhaled Ebola vaccine may offer long-term protection from virus The University of Texas at Austin News, November 7, 2014

11 Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy Clinical Infectious Diseases, January 30, 2014    Clinical Article

12 Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: A meta-analysis of randomized controlled trials Clinical Infectious Diseases, December 2, 2014    Evidence Based Medicine    Clinical Article

13 A systematic review: Can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clinical Infectious Diseases, October 6, 2014    Review Article

14 Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: A meta-analysis of RCTs European Journal of Clinical Microbiology & Infectious Diseases, December 15, 2014    Clinical Article

15 Topical vancomycin in combination with perioperative antibiotics and tight glycemic control helps to eliminate sternal wound infections The Journal of Thoracic and Cardiovascular Surgery, July 17, 2014    Clinical Article

16 Herpes zoster as a risk factor for stroke and TIA Neurology®, January 10, 2014    Clinical Article

17 The return of the big three killers Clinical Microbiology and Infection, July 30, 2013    Clinical Article

18 Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America Clinical Infectious Diseases, June 20, 2014    Clinical Article

19 Ceftaroline: Clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA Diagnostic Microbiology and Infectious Disease, December 4, 2014    Clinical Article

20 Severe vivax malaria: A systematic review and meta-analysis of clinical studies since 1900 Full Text Malaria Journal, December 12, 2014    Free full text

Indexed Journals in Infectious Disease: Journal of Infection, AIDS, American Journal of Infection Controlmore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List